Leflunomide-induced acute hepatitis.
Article Details
- CitationCopy to clipboard
Sevilla-Mantilla C, Ortega L, Agundez JA, Fernandez-Gutierrez B, Ladero JM, Diaz-Rubio M
Leflunomide-induced acute hepatitis.
Dig Liver Dis. 2004 Jan;36(1):82-4.
- PubMed ID
- 14971821 [ View in PubMed]
- Abstract
Leflunomide, a new immunomodulatory agent, was prescribed to a 67-year-old female patient with rheumatoid arthritis. Fifteen days later she developed diarrhoea and elevated liver enzymes. A liver biopsy showed a pattern of acute hepatitis. The patient was homozygous for the rare CYP2C9*3 allele, which determines the slowest metabolic rate for CYP2C9 enzymatic activity, that is probably involved in the metabolism of leflunomide. Liver damage subsided in few weeks. This case illustrates the risk of hepatotoxicity by leflunomide and suggests that it is possibly related to CYP2C9 polymorphism.
DrugBank Data that Cites this Article
- Drug Enzymes
Drug Enzyme Kind Organism Pharmacological Action Actions Leflunomide Cytochrome P450 2C9 Protein Humans UnknownSubstrateInhibitorDetails - Drug Interactions
Drugs Interaction Integrate drug-drug
interactions in your softwareLeflunomideNaltrexone The risk or severity of liver damage can be increased when Naltrexone is combined with Leflunomide. LeflunomideIsoniazid The risk or severity of liver damage can be increased when Isoniazid is combined with Leflunomide. LeflunomideRegorafenib The risk or severity of liver damage can be increased when Regorafenib is combined with Leflunomide. LeflunomideBosentan The risk or severity of liver damage can be increased when Bosentan is combined with Leflunomide. LeflunomideNevirapine The risk or severity of liver damage can be increased when Nevirapine is combined with Leflunomide.